NovoCure Ltd.

How big is NovoCure Ltd.?

As of Jun 18, NovoCure Ltd. has a market capitalization of 1,943.19 million, with net sales of 621.71 million and a net profit of -164.19 million over the latest four quarters.

Market Cap: As of Jun 18, NovoCure Ltd. has a market capitalization of 1,943.19 million, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, NovoCure Ltd. reported net sales of 621.71 million and a net profit of -164.19 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 360.18 million, while total assets were reported at 1,240.78 million.

What does NovoCure Ltd. do?

NovoCure Ltd. is a small-cap oncology company focused on developing cancer treatments using TTFields technology. As of March 2025, it reported net sales of $155 million and a net loss of $34 million.

Overview: <BR>NovoCure Ltd. is a commercial-stage oncology company engaged in developing cancer treatments using a therapy called TTFields, operating within the Pharmaceuticals & Biotechnology industry and categorized as a small-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 155 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -34 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 1,943.19 Million (Small Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.76 <BR>Return on Equity: -45.10% <BR>Price to Book: 5.37<BR><BR>Contact Details: <BR>Address: Forum, NO. 4 Grenville Street, SAINT HELIER None: JE2 4UF <BR>Tel: 44 1534 756700 <BR>Website: https://www.novocure.com/

Should I buy, sell or hold NovoCure Ltd.?

Who are in the management team of NovoCure Ltd.?

As of March 2022, NovoCure Ltd.'s management team includes Executive Chairman William Doyle, CEO Asaf Danziger, Lead Independent Director William Vernon, and several Independent Directors: Jeryl Hilleman, David Hung, Kinyip Gabriel Leung, and Martin Madden.

As of March 2022, the management team of NovoCure Ltd. includes the following individuals:<BR><BR>- Mr. William Doyle, who serves as the Executive Chairman of the Board.<BR>- Mr. Asaf Danziger, who holds the positions of President, Chief Executive Officer, and Director.<BR>- Mr. William Vernon, who is the Lead Independent Director.<BR>- Ms. Jeryl Hilleman, an Independent Director.<BR>- Dr. David Hung, also an Independent Director.<BR>- Mr. Kinyip Gabriel Leung, serving as an Independent Director.<BR>- Mr. Martin Madden, who is another Independent Director.<BR><BR>In summary, as of March 2022, NovoCure Ltd.'s management team consists of key figures including the Executive Chairman, CEO, and several Independent Directors.

Is NovoCure Ltd. overvalued or undervalued?

As of July 29, 2021, NovoCure Ltd. is considered risky and overvalued due to its high Price to Book Value of 5.24, negative EV to EBIT and EV to EBITDA ratios, and a concerning ROCE of -190.50%, with a year-to-date return of -56.38% compared to the S&P 500's 12.22%.

As of 29 July 2021, the valuation grade for NovoCure Ltd. moved from fair to risky, indicating a more cautious outlook on the stock. The company appears to be overvalued given its high Price to Book Value of 5.24 and negative EV to EBIT and EV to EBITDA ratios of -9.77 and -10.51, respectively. Additionally, the Return on Capital Employed (ROCE) stands at a concerning -190.50%, further emphasizing the company's struggles.<BR><BR>In comparison to its peers, NovoCure's EV to EBITDA ratio of -7.2229 is significantly worse than that of TransMedics Group, which has a fair valuation with an EV to EBITDA of 37.0142. Other risky peers like iRhythm Technologies show an even more negative EV to EBITDA of -145.8167. The stock's performance has lagged behind the S&P 500, with a year-to-date return of -56.38% compared to the index's 12.22%, reinforcing the notion that NovoCure is currently overvalued.

Is NovoCure Ltd. technically bullish or bearish?

As of September 12, 2025, NovoCure Ltd. has shifted to a bearish technical trend, with significant underperformance compared to the S&P 500, reflecting a year-to-date return of -56.38% versus the S&P 500's 12.22%.

As of 12 September 2025, the technical trend for NovoCure Ltd. has changed from mildly bearish to bearish. The weekly MACD is bearish, and the daily moving averages indicate a mildly bearish stance. Bollinger Bands are also showing a mildly bearish trend on both weekly and monthly time frames. The KST is bearish on a weekly basis, while the monthly remains mildly bullish, indicating some divergence. Overall, the Dow Theory shows no trend on a weekly basis and mildly bearish on a monthly basis.<BR><BR>In terms of performance, NovoCure has underperformed significantly compared to the S&P 500, with a year-to-date return of -56.38% versus the S&P 500's 12.22%, and a 3-year return of -85.05% compared to the S&P 500's 70.41%. This highlights a stark contrast in performance, reinforcing the bearish technical stance.